Streetbeat News

Regulatory

KZR

Trading of Kezar Life Sciences shares has been halted due to pending news.

Portfolio Pulse from Bill Haddad

October 03, 2023 | 8:07 pm

SPY

The U.S. House of Representatives has begun voting on a motion to oust Speaker McCarthy, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 8:02 pm

FXI

SPY

U.S. Treasury Secretary Yellen has expressed concerns over the U.S.'s over-dependence on China in areas of national well-being, while also stating that she doesn't believe the U.S. should decouple from China.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 7:37 pm

AMGN

The FDA has raised concerns over Amgen Inc's lung cancer drug, Lumakras, ahead of the Oncologic Drugs Advisory Committee meeting. The FDA staff reviewers suggested that the company's late-stage trial might not be considered 'adequate and well-controlled'. While Lumakras was approved by the FDA in May 2021, the recent findings imply the potential need for an additional confirmatory trial. Despite this, the commercial prospects for Lumakras might be mitigated by encouraging outcomes in colorectal cancer treatments and additional planned combination studies.

Portfolio Pulse from Vandana Singh

October 03, 2023 | 7:30 pm

SPY

U.S. Treasury Secretary Janet Yellen has stated that debt service costs will be 1% of GDP for the next decade, assuming deficit reduction. This statement could have implications for the overall U.S. economy and the stock market.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 7:23 pm

ATAI

Clinical-stage biopharma company atai Life Sciences (NASDAQ:ATAI) has completed its Phase 1 study of proprietary oral transmucosal film (OTF) DMT formulation VLS-01 in 74 healthy participants. The study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of VLS-01. The results showed that the compound was well-tolerated with a favorable safety profile. The company now plans to test an optimized version of its OTF formulation in an upcoming Phase 1b trial before initiating a Phase 2 in Treatment-Resistant Depression patients.

Portfolio Pulse from Lara Goldstein

October 03, 2023 | 7:23 pm

META

Meta Platforms, Inc. (NASDAQ:META) is reportedly exploring a $14/month subscription plan for European users to comply with EU regulations on personalized ads. This comes after a $1.3 billion fine against the company in May for violating the EU’s data privacy regulations. Shares of META were down 2.03% at $300.59 at the time of publication.

Portfolio Pulse from Ryan Gustafson

October 03, 2023 | 7:19 pm

BNTX

MRNA

NVAX

PFE

Novavax Inc's shares surged after the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization for its updated Covid-19 vaccine, Adjuvanted (2023-2024 Formula), for individuals aged 12 and older. This comes less than a month after the FDA approved updated vaccines from Moderna Inc and the joint vaccine from Pfizer Inc and BioNTech SE.

Portfolio Pulse from Adam Eckert

October 03, 2023 | 7:17 pm

BTCUSD

Countries worldwide are investing in blockchain technology and cryptocurrency, with Singapore, Switzerland, South Korea, Malta, the U.S., and UAE leading the way. Singapore recently received a Major Payment Institution license, enabling it to offer Digital Payment Token services. South Korea disclosed $98.5 billion in foreign cryptocurrency assets. The U.S. leads in blockchain innovations and venture capital investments. The UAE is exploring blockchain technology across various industries. The global blockchain tech market is expected to reach $1.432 billion by 2030, and the global Fintech Blockchain Market is projected to expand to $21.67 billion by 2028.

Portfolio Pulse from Khyathi Dalal

October 03, 2023 | 7:14 pm

MKUL

Trading of Molekule Group's shares has been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 7:02 pm